Siliq is called Kyntheum in Europe.
Siliq contains a protein called brodalumab, a monoclonal antibody. Brodalumab blocks the activity of IL17 proteins, which are elevated in diseases such as psoriasis.
Siliq is used to treat moderate to severe plaque psoriasis, a skin condition which causes redness and inflammation and scaly plaque formation affecting large portions of the body. Siliq reduces signs and symptoms of psoriasis (itch, scaling, burning, cracking, pain, flaking, and redness) and leads to an improvement of skin clearance.
Information about Siliq (Brodalumab)
Siliq is a brand name for brodalumab, a biologic medication used primarily for the treatment of moderate to severe plaque psoriasis. It is a monoclonal antibody that targets specific proteins involved in the inflammatory process of psoriasis, helping to reduce the overproduction of skin cells and inflammation.
Product Highlights
- Siliq is primarily used to treat adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have not responded well to other treatments, such as conventional systemic therapies.
- Although not its primary indication, brodalumab has been studied for use in psoriatic arthritis in some patients.
Key Ingredient
Key Benefits
- Siliq is highly effective in reducing the symptoms of moderate-to-severe plaque psoriasis, helping to clear or significantly reduce psoriatic plaques on the skin.
- Many patients experience significant improvement in skin condition within the first few weeks of treatment.
- After the initial loading phase, the medication is given at regular intervals, providing sustained relief of psoriasis symptoms.
- By reducing the severity of psoriasis, Siliq helps improve the overall quality of life for individuals suffering from the condition.
Direction of Use
- Siliq is administered as a subcutaneous injection (under the skin), usually in a healthcare setting during the initial phase of treatment.
- The initial dosing regimen consists of a loading dose of Siliq (administered at weeks 0, 1, and 2), followed by maintenance injections every 4 weeks.
- After the loading phase, patients may be trained to administer the injection at home if they are stable and have no contraindications.
Safety Concerns
- There is a black box warning for Siliq regarding an increased risk of suicidal thoughts and behaviors. Patients should be monitored for signs of depression or suicidal ideation, especially during the first few months of treatment.
- As a biologic agent that affects the immune system, Siliq can increase the risk of infections, including tuberculosis (TB), fungal infections, and respiratory infections. TB screening is recommended before starting treatment.
- There have been reports of inflammatory bowel disease (IBD) exacerbations, including Crohn's disease and ulcerative colitis, in some patients using Siliq.
- Like other biologics, Siliq can cause allergic reactions, ranging from mild skin rashes to more serious symptoms like difficulty breathing. Severe allergic reactions require immediate medical attention.
- Uveitis (inflammation of the eye) has been reported in some patients taking Siliq.
Avoid Siliq (Brodalumab) If
- Siliq should be avoided in patients with a history of suicidal ideation or behaviors, or those who have significant depression, as the drug may increase the risk of these issues.
- Patients with active infections, including tuberculosis, should not receive Siliq until the infection is controlled or treated.
- Individuals with a history of inflammatory bowel disease or those who experience exacerbations of IBD should not use Siliq.
- If a patient has a known hypersensitivity to brodalumab or any of the ingredients in Siliq, they should avoid using the medication.
- Due to limited safety data, it is not recommended for use during pregnancy or breastfeeding. Women should consult their healthcare provider to discuss potential risks.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
